Author:
Muñoz Gómez M.,Bisbe Vives E.,Basora Macaya M.,García Erce J.A.,Gómez Luque A.,Leal-Noval S.R.,Colomina M.J.,Comin Colet J.,Contreras Barbeta E.,Cuenca Espiérrez J.,Garcia de Lorenzo y Mateos A.,Gomollón García F.,Izuel Ramí M.,Moral García M.V.,Montoro Ronsano J.B.,Páramo Fernández J.A.,Pereira Saavedra A.,Quintana Diaz M.,Remacha Sevilla Á.,Salinas Argente R.,Sánchez Pérez C.,Tirado Anglés G.,Torrabadella de Reinoso P.
Subject
Critical Care and Intensive Care Medicine
Reference98 articles.
1. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines [consultado Nov 2013]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144874.pdf
2. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Nota informativa. Preparados de hierro de administración intravenosa y reacciones de hipersensibilidad: nuevas recomendaciones. Fecha de publicación: 2 de julio de 2013 [consultado Nov 2013]. Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2013/docs/NI-MUH_FV_20-2013-hierro_intravenoso.pdf
3. European Medicines Agency. Annex III. Wording to be included in the Summary of Products Characteristics and Package Leaflet of tranexamic acid containing medicinal products listed in Annex I (as adopted by the CHMP on 19 June 2012) [consultado Nov 2013]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Antifibrinolytic_medicines/WC500122923.pdf
4. European Medicines Agency. European Medicines Agency recommends lifting suspension of aprotinin. February 2012 [consultado Nov 2013]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/02/WC500122914.pdf
5. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl starch. EMA/349341/2013 [consultado Jun 2014]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Solutions_for_infusion_containing_hydroxyethyl_starch/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500144448.pdf